Do Eye Vitamins Really Work? What the Evidence Shows

Do eye vitamins really work? For most people, no. For one clearly defined group — people who already have intermediate age-related macular degeneration, or advanced AMD in one eye — one specific formula does measurably slow the disease. Outside that group, the evidence thins out fast.

That gap between who the pills were proven to help and who they are sold to is the whole story of this category. We read the trial data and the formula labels rather than testing supplements ourselves, because the question here is not how a capsule feels — it is whether a large randomized trial ever showed it doing anything. Below is what those trials found, why the drugstore shelf oversells them, and where your money and attention do more good. If you are still mapping out the bigger picture, start with how eye health changes after 50.

The Short Answer: One Formula, One Group of People

There is essentially one eye supplement with serious randomized evidence behind it, and it is not a general "vision support" pill. It is the AREDS2 formula, studied by the National Eye Institute (NEI).

According to the National Eye Institute, the AREDS2 formula contains 500 mg of vitamin C, 400 IU of vitamin E, 10 mg of lutein, 2 mg of zeaxanthin, 80 mg of zinc, and 2 mg of copper. Those are the doses that were tested. That is also the ceiling of what the evidence covers.

And the NEI is blunt about who it helps. Its guidance states that there was no benefit for people with early AMD or for people who do not have AMD. The agency also notes that nutritional supplements cannot prevent AMD in the first place, and describes their role as delaying progression from intermediate to advanced AMD and helping people keep their vision longer. The American Academy of Ophthalmology puts the limit plainly: supplements are not a cure for AMD.

So if you have healthy eyes and you are taking an eye vitamin as insurance, you are taking a supplement outside the population it was proven in.

What the AREDS Trials Actually Tested

Two trials carry almost all the weight here, and it helps to know exactly what each one asked.

The original Age-Related Eye Disease Study (AREDS) enrolled 4,757 participants aged 55 to 80, recruited between November 1992 and January 1998, according to the National Eye Institute. It tested high-dose antioxidants plus zinc against placebo. The headline result: among participants at highest risk — those with intermediate AMD, or advanced AMD in one eye — the formulation reduced the risk of progressing to advanced AMD by about 25 percent over five years.

AREDS2 came next, and it asked a narrower question: could the formula be improved? The National Eye Institute reports that AREDS2 enrolled 4,203 participants aged 50 to 85 across 82 clinical sites, and deliberately included only people with intermediate AMD in both eyes, or intermediate AMD in one eye and advanced AMD in the other — those with no AMD or early AMD were excluded, because the earlier AREDS data had shown no benefit for them.

The result was largely a null one. Per the NEI, adding omega-3 fatty acids or lutein plus zeaxanthin to the original formula had no additional overall effect on the risk of advanced AMD. The useful finding came from a swap rather than an addition, and we will get to that below.

Who Genuinely Benefits

The honest list is short.

• People with intermediate AMD in one or both eyes. This is the group the 25 percent figure comes from.
• People with advanced AMD in one eye, where the goal is protecting the other eye.

That is it. And even within that group, the benefit is a slowing of progression, not a cure and not a vision improvement. Roughly a quarter fewer people progressing over five years is genuinely worth having if you are in that group — it is just not what the phrase "eye vitamins" implies to most shoppers.

There is one more wrinkle worth knowing. The National Eye Institute notes that AREDS2 participants taking lutein and zeaxanthin without beta-carotene had an 18 percent lower risk of progressing to advanced AMD than those on the original beta-carotene formula, and that the difference rose to 26 percent among participants whose ordinary diets were lowest in those nutrients. In other words, the people with the least lutein on their plates had the most to gain from a capsule.

If an eye doctor has told you that you are in one of these categories, the practical next question is which formula to buy — and we cover that in our guide to the best eye vitamins for aging eyes.

Who Almost Certainly Does Not Benefit

If you are buying an eye vitamin for any of the following reasons, the evidence is not with you.

• You have healthy eyes and want to prevent AMD. A Cochrane review of antioxidant vitamin and mineral supplements for preventing AMD concluded that taking vitamin E or beta-carotene will not prevent the onset of AMD in people with no signs of the condition, that the same probably applies to vitamin C and multivitamins, and that there is no evidence for other supplements such as lutein and zeaxanthin. The reviewers' own conclusion was that although such supplements are generally regarded as safe, they may have harmful effects, and clear evidence of benefit is needed before they can be recommended.
• You want sharper vision, or to put off reading glasses. Nothing in the AREDS data speaks to this. Age-related focusing changes are a mechanical problem with the lens, not a nutrient shortfall.
• You have early AMD. The NEI is explicit that the formula showed no benefit at this stage.

That pattern — real but narrow benefit, marketed as broad benefit — is the same one we found when we looked at whether longevity supplements actually work. The category is not a scam so much as a mis-sale.

The Beta-Carotene Problem That Rewrote the Formula

This is the safety story behind the formula change, and it is worth getting right.

The original AREDS formula used beta-carotene. But two large cancer-prevention trials had already found trouble with it in smokers. According to the National Cancer Institute, the ATBC study of 29,133 male smokers found a statistically significant 18 percent increase in lung cancer incidence (relative risk 1.18) and an 8 percent increase in overall mortality among men randomized to 20 mg of beta-carotene daily. The CARET trial, which enrolled 18,314 smokers, former smokers, and asbestos-exposed workers, was terminated early after confirming a harmful effect, with a relative risk of 1.28 for lung cancer.

AREDS2 saw an echo of this. The National Eye Institute reports that lung cancers were observed in 2 percent of participants who took an AREDS formulation containing beta-carotene, compared with 0.9 percent of those who took a formulation without it. About half of AREDS2 participants were former smokers.

The practical upshot: beta-carotene was dropped and lutein plus zeaxanthin took its place. As NEI's Wai T. Wong put it in the agency's announcement of the long-term results, removing beta-carotene "simplifies things. We have identified a formulation that should be good for everyone regardless of smoking status." If you smoke or used to, this is the single most important paragraph on this page — check the label for beta-carotene.

One more label note: the NEI reports that AREDS2 testing did not find a difference in effect between 80 mg and 25 mg of zinc, so a lower-zinc version is not a weaker product on the evidence.

What About Cataracts, Dry Eye, and Screen Strain?

Three claims come up constantly on eye-vitamin packaging. None of them holds up the way the AMD claim does.

Cataracts. The National Eye Institute states that the AREDS supplements had no effect on cataract overall, with a benefit appearing only in one subgroup analysis. The American Academy of Ophthalmology likewise says there is insufficient evidence to support the routine use of nutritional supplements for primary prevention of eye diseases such as AMD and cataracts.

Dry eye. The best test of the popular omega-3 claim was the NEI-funded DREAM trial, which randomized 535 people with moderate to severe dry eye and gave one group 3 grams of fish-derived omega-3s daily — the highest dose ever tested for this purpose. According to the National Eye Institute, the supplements were no better than placebo at relieving symptoms or signs, and the results were published in the New England Journal of Medicine. We will cover what does help in a separate piece on dry eye after 50.

Screen strain and "digital eye" formulas. These rest on the lutein-and-blue-light idea rather than on outcome trials in people with tired eyes. Treat the claims as unproven.

Why the Bottle on the Shelf May Not Match the Trial

Even readers who genuinely need the AREDS2 formula often do not get it, because "eye vitamin" is a marketing category, not a regulated one.

The American Academy of Ophthalmology reported on an analysis of 11 top-selling eye supplements and found that only four contained doses equivalent to the AREDS or AREDS2 ingredients. Four contained lower doses, and four added extra vitamins, minerals, or herbal extracts that were never part of the trials. All 11 made broad promotional claims about supporting vision, and none stated that these nutrients have been proven effective only in people at specific stages of AMD.

The regulatory backdrop explains how that is possible. According to the FDA, there are no provisions in the law for the agency to approve dietary supplements for safety before they reach consumers, and it does not approve supplement labeling in advance. Manufacturers are responsible for substantiating their own structure/function claims, which must carry a disclaimer that the statement has not been evaluated by the FDA.

The marketing has occasionally crossed the line into enforcement. The Federal Trade Commission announced in 2005 that the seller of an "ocular nutrition" supplement paid $450,000 to settle charges over unsubstantiated claims that the product could restore vision already lost to macular degeneration and eliminate floaters.

Naming conventions add to the confusion. Shoppers now see AREDS2 and AREDS3 formulas side by side, and the newer label implies a newer trial. It does not describe one: the National Eye Institute has run two AREDS studies, and according to the manufacturer, the AREDS3 product adds a B-vitamin complex on top of the AREDS2 nutrients. The B vitamins are the company's addition, not an NEI trial result.

High doses also deserve respect rather than casualness. The Academy notes that any high-dose supplement may interfere with other medications, which is why a full list of your supplements and prescriptions belongs in front of your provider — the same principle we lay out in our guide to supplement safety after 50.

Where Diet Beats a Pill

Notice the detail buried in the AREDS2 subgroup finding: the biggest supplement benefit went to participants who were eating the least lutein and zeaxanthin to begin with. That is a strong hint about where to start.

The American Academy of Ophthalmology points to food sources for each of the nutrients in question: leafy greens such as kale, spinach, collard greens, and Swiss chard, plus broccoli, asparagus, raspberries, papaya, peaches, and mangoes for lutein and zeaxanthin; citrus, kiwifruit, strawberries, tomatoes, and peppers for vitamin C; almonds, sunflower seeds, olive oil, and avocados for vitamin E; legumes, seeds, meat and seafood, dairy, and eggs for zinc; and oily fish such as salmon, trout, and sardines for omega-3s.

Food will not substitute for the AREDS2 formula if you have intermediate AMD — the trial doses are far above dietary levels. But for everyone else, a plate built that way is the version of "eye nutrition" with actual support behind it, and it overlaps almost entirely with our broader advice on supplements for healthy aging.

What to Ask Your Eye Doctor

If you want a single useful outcome from this article, it is a better conversation at your next exam. Worth asking:

• What stage of AMD do I have, if any? Early, intermediate, and advanced are different answers with different recommendations, and the supplement question hinges entirely on this.
• Do you recommend the AREDS2 formula for me specifically? The Academy's advice is to talk with your ophthalmologist before stocking up.
• Does the product I am holding match the tested doses? Bring the bottle or a photo of the label.
• Does this interact with anything else I take? Especially relevant for high-dose zinc.
• Should I avoid beta-carotene? If you smoke or used to, say so plainly.

The Bottom Line

Do eye vitamins really work? For people with intermediate AMD or advanced AMD in one eye, one specific formula reduced progression to advanced disease by roughly a quarter over five years — a real, worthwhile result. For healthy eyes, early AMD, blurry reading vision, or general "vision support," the evidence does not back the purchase, and the Cochrane reviewers concluded that clear evidence of benefit is needed before these supplements can be recommended to people who do not yet have AMD. Eating the greens and booking the eye exam is the better-supported use of the money; whether a capsule belongs on top of that depends on what stage, if any, your eye doctor finds. For the full picture of what changes with age and what actually helps, see Better Life Span's guide to eye health after 50.

This article is general information, not medical advice. Your stage of AMD, your medications, and your smoking history all change the answer, so talk with an eye doctor or physician about your own situation before starting or stopping any supplement. And if you notice sudden vision changes, eye pain, or new floaters or flashes of light, get seen promptly rather than reaching for a bottle — those are symptoms that need an exam, not a vitamin.